

## Res. Asst. PhD Nijat KHANMAMMADOV

### Personal Information

Office Phone: [+90 414 243 4](tel:+904142434)

Fax Phone: [+90 521 420 3](tel:+905214203)

Email: [nijat.khanmammadov@istanbul.edu.tr](mailto:nijat.khanmammadov@istanbul.edu.tr)

Web: <https://avesis.istanbul.edu.tr/nijat.khanmammadov>

### International Researcher IDs

ORCID: 0000-0002-3652-8195

### Education Information

Post Doctorate of Medicine, Istanbul University, Istanbul Medical Faculty, Division Of Medical Sciences , Turkey 2019 - Continues

### Foreign Languages

English, B1 Intermediate

### Dissertations

Expertise In Medicine, Beta talasemi minörde serum endokan düzeyi / Serum endocan levels in beta thalassemia minor, Istanbul University, 2019

### Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Therapeutic efficacy of high-dose chemotherapy with autologous stem-cell transplantation in 44 relapsed or refractory germ-cell tumor patients: A retrospective cohort study**  
Ferhatoglu F., Paksoy N., Khanmammadov N., YILDIZ A., AHMED M. A., Gülbas Z., BAŞARAN M.  
Medicine, vol.103, no.8, 2024 (SCI-Expanded)
- II. **Comparative analysis of doublet chemotherapy regimens plus bevacizumab in patients with recurrent ovarian cancer**  
Khanmammadov N., Doğan I., Okay N. S., AZİZY A., Saip P., AYDINER A.  
Medicine (United States), vol.103, no.1, 2024 (SCI-Expanded)
- III. **Outcomes of the patients with metastatic male breast cancer**  
Dogan I., Khanmammadov N., ÖZKURT S., AYDINER A., Saip P.  
Journal of Cancer Research and Therapeutics, vol.20, no.1, pp.98-102, 2024 (SCI-Expanded)
- IV. **Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression**  
DOĞAN İ., Aydin E., KHANMAMMADOV N., Paksoy N., Saip P., AYDINER A.  
Scientific Reports, vol.13, no.1, 2023 (SCI-Expanded)
- V. **Long-term outcomes and predictors of recurrence in node-negative early stage breast cancer patients**  
DOĞAN İ., Aydin E., KHANMAMMADOV N., Paksoy N., Ferhatoglu F., AK N., Emiroglu S., İBİŞ K., Onder S., Tukenmez

M., et al.

Journal of Cancer Research and Clinical Oncology, vol.149, no.16, pp.14833-14841, 2023 (SCI-Expanded)

- VI. **Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience**  
TAŞTEKİN D., Paksoy N., DOĞAN İ., Ferhatoglu F., KHANMAMMADOV N., Bozbey H. U., KARABULUT S.  
Journal of cancer research and therapeutics, vol.19, no.2, pp.253-258, 2023 (SCI-Expanded)
- VII. **Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group**  
GÜRBÜZ M., Kilickap S., BİLİCİ A., Karadurmus N., Sezer A., ŞENDUR M. A. N., PAYDAŞ S., ARTAÇ M., Fulden Yumuk P., GÜRSOY P., et al.  
MEDICINE, vol.101, no.50, 2022 (SCI-Expanded)
- VIII. **High-dose chemotherapy followed by autologous stem cell transplantation for adult patients with first relapse of Ewing's sarcoma: A single institution experience**  
PAKSOY N., FERHATOĞLU F., DOĞAN İ., KHANMAMMADOV N., Iribas Celik A., Gulbas Z., BAŞARAN M.  
Medicine (United States), vol.101, no.49, 2022 (SCI-Expanded)
- IX. **Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study**  
PAKSOY N., KHANMAMMADOV N., DOĞAN İ., FERHATOĞLU F., YILDIZ A., AK N., AYDINER A.  
Medicine (United States), vol.101, no.45, 2022 (SCI-Expanded)
- X. **Assessment of serum endocan levels in patients with beta-thalassemia minor**  
Khanmammadov N., ZORLU M., ÖZER Ö. F., KARATOPRAK C., KISKAÇ M., ÇAKIRCA M.  
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, vol.68, no.2, pp.147-151, 2022 (SCI-Expanded)

## Articles Published in Other Journals

- I. **Efficacy of Bevacizumab-Based Therapy in Patient With Metastatic or Recurrent Cervical Cancer: Real Life Data**  
KHANMAMMADOV N., Dogan I., okay n. s., Ugar M., Osmanova N., Saip P., Aydiner A.  
Selçuk Tıp Dergisi, vol.40, no.2, pp.68-73, 2024 (Peer-Reviewed Journal)
- II. **The Effect of Adjuvant Therapies for Recurrence in Stage I Breast Cancer Patients: A Single Centre Experience**  
Doğan İ., Khanmammadov N., Aydin E., PAKSOY N., Ferhatoğlu F., AK N., Emiroğlu S., İBİŞ K., Önder S., Tükenmez M., et al.  
Turk Onkoloji Dergisi, vol.39, no.3, pp.257-264, 2024 (ESCI)
- III. **Evaluation of the Efficacy of Bevacizumab-based Therapies in Patients with Platinum-Resistant or-Allergic Metastatic Ovarian Cancer**  
Khanmammadov N., Doğan İ., Okay N. S., YILDIZ A., Khishigsuren B., AZİZY A., Saip P., AYDINER A.  
Turk Onkoloji Dergisi, vol.39, no.2, pp.176-182, 2024 (ESCI)
- IV. **Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors**  
DOĞAN İ., KHANMAMMADOV N., PAKSOY N., VATANSEVER S., SAİP P., AYDINER A.  
Eurasian Journal of Pulmonology, vol.25, no.1, pp.27-32, 2023 (Peer-Reviewed Journal)
- V. **Weekly paclitaxel treatment in the first-line therapy of classic Kaposi sarcoma: A real-life study**  
Paksoy N., KHANMAMMADOV N., DOĞAN İ., Ferhatoğlu F., AHMED M. A., Karaman S., AYDINER A.  
Medicine (Spain), vol.102, no.5, 2023 (Scopus)
- VI. **Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib**  
DOĞAN İ., Khanmammadov N., Ahmed M. A., Yildiz A., Saip P., Aydiner A., VATANSEVER S.  
CLINICAL CANCER INVESTIGATION JOURNAL, no.4, pp.5-9, 2022 (ESCI)
- VII. **Crizotinib in Metastatic ALK mutant Non-small Cell Lung Cancer Patients: A Single Centre Experience**

DOĞAN İ., Khanmammadov N., Ahmed M. A., Yildiz A., Saip P., Aydiner A., VATANSEVER S.

CLINICAL CANCER INVESTIGATION JOURNAL, no.3, pp.25-29, 2022 (ESCI)

VIII. **Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study**

Paksoy N., Ferhatoglu F., DOĞAN İ., Khanmammadov N., Bozbey H. U., KARABULUT S., Tastekin D.

TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.37, no.4, pp.478-483, 2022 (ESCI)

## **Refereed Congress / Symposium Publications in Proceedings**

I. **Comparison of bevacizumab plus doublet chemotherapy regimens in patients with metastatic or recurrent ovarian cancer.**

Khanmammadov N., DOĞAN İ., Saip P., Aydiner A.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2 - 06 June 2023

## **Metrics**

Publication: 19

Citation (WoS): 1

Citation (Scopus): 8

H-Index (WoS): 1

H-Index (Scopus): 2